CAR- and TRuC-redirected regulatory T cells differ in capacity to control adaptive immunity to FVIII

Jyoti Rana,1 Daniel J. Perry,2 Sandeep R.P. Kumar,1 Maite Muñoz-Melero,1 Rania Sabouni,3 Todd M. Brusko,2,4 and Moanaro Biswas1

Regulatory T cells (Tregs) control immune responses in autoimmune disease, transplantation, and enable antigen-specific tolerance induction in protein-replacement therapies. Tregs can exert a broad array of suppressive functions through their T cell receptor (TCR) in a tissue-directed and antigen-specific manner. This capacity can now be harnessed for tolerance induction by “redirecting” polyclonal Tregs to overcome low inherent precursor frequencies and simultaneously augment suppressive functions. With the use of hemophilia A as a model, we sought to engineer antigen-specific Tregs to suppress antibody formation against the soluble therapeutic protein factor (F)VIII in a major histocompatibility complex (MHC)-independent fashion. Surprisingly, high-affinity chimeric antigen receptor (CAR)-Treg engagement induced a robust effector phenotype that was distinct from the activation signature observed for endogenous thymic Tregs, which resulted in the loss of suppressive activity. Targeted mutations in the CD3ζ or CD28 signaling motifs or interleukin (IL)-10 overexpression were not sufficient to restore tolerance. In contrast, complexing TCR-based signaling with single-chain variable fragment (scFv) recognition to generate TCR fusion construct (TRuC)-Tregs delivered controlled antigen-specific signaling via engagement of the entire TCR complex, thereby directing functional suppression of the FVIII-specific antibody response. These data suggest that cellular therapies employing engineered receptor Tregs will require regulation of activation thresholds to maintain optimal suppressive function.

INTRODUCTION

FoxP3-expressing regulatory T cells (Tregs) are crucial drivers of central and peripheral tolerance and are therefore an ideal cellular therapeutic tool for antigen-specific tolerance induction. In human clinical trials, single infusions of polyclonal Tregs can successfully prevent or attenuate autoimmune disease1,2 as well as allogeneic hematopoietic cell or solid organ transplant rejection,3,4 thus reducing dependency on immunosuppressive drugs. Tregs can further be redirected for antigen specificity using cutting-edge cellular engineering mechanisms, thereby improving targeted suppression at lower effective doses.5,6

One strategy to engineer specificity in polyclonal Tregs is to express a chimeric antigen receptor (CAR), which is a synthetic molecule that combines extracellular single-chain variable fragments (scFvs) of an antibody with primary T cell receptor (TCR) signaling and costimulatory moieties.1 Alternatively, this strategy can potentially be applied to FoxP3-engineered conventional T cells (Tconvs) under conditions of Treg scarcity.5,6 CAR expression combines antigen specificity and cell signaling without the requirement for major histocompatibility complex (MHC) class II restriction in a diverse patient group. CAR-engineered Tconvs have been shown to be highly effective at eradicating B cell leukemias that are resistant to standard therapies, whereas studies with CAR Tregs show promise in models of autoimmune disease11,12 and allograft rejection.5,6 with a first-in-man clinical trial soon to be launched for solid organ transplantation (phase I/II STEADFAST trial, TX200; Sangamo Therapeutics). To date, CAR Treg design has been modeled on CAR Tconv constructs for cancer eradicating B cell leukemias that are resistant to standard therapies, whereas studies with CAR Tregs show promise in models of autoimmune disease11,12 and allograft rejection.5,6 with a first-in-man clinical trial soon to be launched for solid organ transplantation (phase I/II STEADFAST trial, TX200; Sangamo Therapeutics). To date, CAR Treg design has been modeled on CAR Tconv constructs for cancer

In this study, we used a high-affinity CAR specific for coagulation factor (F)VIII to suppress inhibitory antibody responses to replacement FVIII therapy in a murine model of hemophilia A (HA). Mutations in the F8 gene can lead to reduced, misfolded, or complete lack of
expression of FVIII in the blood, with severity of the condition consistent with the degree of residual clotting activity.\textsuperscript{15,16} Inhibitory antibodies to exogenously infused FVIII can neutralize the therapeutic protein in up to 30% of severe HA patients, thus interfering with treatment. A growing body of evidence suggests that immunomodulation by Tregs could offer a new treatment strategy in HA.\textsuperscript{17} We have previously shown that cellular therapy with either ex vivo-expanded polyclonal Tregs or FoxP3-transduced Tconv (i.e., de novo Tregs) enriched for antigen specificity is tolerogenic in a murine model of severe HA.\textsuperscript{18,19}

Here, we sought to understand the effect of high-affinity CAR signaling on Treg stability, cytokine production, in vivo persistence, and suppressive capacity. We analyzed the contribution of proximal and distal CD3\varepsilon immune receptor tyrosine-based activation motifs (ITAMs), as well as CD28 signaling motifs. We explored the alternative TCR fusion construct (TruC), which was synthesized by fusing the FVIII scFv to the N terminus of the TCRs subunit.\textsuperscript{20} We confirmed that incorporation of the TruC construct into the TCR-CD3 complex limited surface receptor density and more faithfully mimicked physiological TCR signaling. In vivo, TruC Tregs suppressed the development of adaptive immune responses to FVIII. Complexing TCR-based signaling with scFv recognition has not been tested earlier in Tregs and has the potential to engage not just the complete TCR machinery in an MHC-unrestricted manner but can also subject the cell to negative-feedback mechanisms that are rapidly induced by TCR engagement to regulate signal output in response to antigen.\textsuperscript{21}

RESULTS

Generation of a FVIII-directed CAR for engineered specificity

We synthesized a second-generation FVIII CAR construct comprising a high-affinity (10^{-11} M^{-1}) extracellular human scFv (B2C11, which was specific for the highly immunogenic C2 domain of FVIII),\textsuperscript{22} complexed to the transmembrane and intracellular murine CD28 costimulatory and CD3\varepsilon signaling domains (Figure 1A). Tregs from BALB/c Foxp3\textsuperscript{IREs-GFP} mice, which express GFP under control of the mouse Foxp3 promoter, were magnetically enriched and purified by fluorescence-activated cell sorting (FACS; >98% FoxP3\textsuperscript{GFP+} cells). Following transduction of activated Tregs with the FVIII CAR-pMYs-ires-mScarlet retroviral vector, mScarlet-and FoxP3\textsuperscript{GFP+}-co-expressing Tregs were FACS sorted for a 2nd time (>98% mScarlet’FoxP3\textsuperscript{GFP+}) and ex vivo expanded for a short period (3–4 days) to obtain ~2-fold expansion (Figure 1B). This was done in order to minimize phenotypic or functional differences that may arise as a result of prolonged ex vivo culture.

Detection of the c-Myc epitope tag on transduced Tregs confirmed surface scFv expression. Binding of Fc-conjugated B domain-deleted (BDD)-FVIII (FVIIIFc) was highly sensitive (Figures 1C and S1). Transduced murine FVIII CAR Tregs upregulated Treg-associated activation markers CD69, latency associated peptide (LAP), glucocorticoid-induced TNFR-related protein (GITR), FoxP3, Ki67, and surface CD28 upon stimulation with BDD-FVIII or FVIIIFc for 48 h (Figure 1D). In vitro-stimulated CellTrace Violet (CTV)-labeled CAR Tregs proliferated in an antigen-specific manner (division index 3.20 ± 0.007; Figure 1E), although proliferation was limited in the absence of exogenous interleukin (IL)-2 in the culture media. Lack of activation/proliferation in unstimulated cells or upon stimulation with an irrelevant antigen, FIXFc, suggested that tonic signaling in the absence of cognate ligand did not occur.

ITAM mutations in FVIII CAR Tregs increase persistence

In vitro stimulation of FVIII CAR Tconvs with either BDD-FVIII or FVIIIFc resulted in a significant loss of viability (Figure 2A). We hypothesized that the additive signaling effect contributed by all three pairs of CD3\varepsilon ITAMs might be responsible for activation-induced cell death (AICD) in these transduced cells.\textsuperscript{23–25} We therefore mutated either the proximal (ITAM1\textsuperscript{varepsilon}) or distal (ITAM3\textsuperscript{varepsilon}) tyrosine residues in CD3\varepsilon as indicated in the schematic in Figure 1A. Mutating either ITAM1\textsuperscript{varepsilon} or ITAM3\textsuperscript{varepsilon} in order to disrupt the extent of CD3\varepsilon signaling significantly prevented AICD in BDD-FVIII-stimulated FVIII CAR Tconv (Figure 2A). On the other hand, mutating both the proximal and distal residues (ITAM1–3\textsuperscript{varepsilon}) completely abrogated CAR signaling and had no effect on viability (Figure 2A). Interestingly, FVIII-stimulated wild-type (WT) CAR Tregs did not develop AICD or any associated cytoxicity (Figure 2B), indicating comparative resistance to apoptosis. Single ITAM mutations did not markedly impede CAR Treg function, as expression of activation markers, CD69 and Ki67, did not differ significantly among FVIII-stimulated WT or ITAM1\textsuperscript{varepsilon}– or ITAM3\textsuperscript{varepsilon}–mutated CAR Tregs (Figures S2A–S2C). Following adoptive transfer and subsequent BDD-FVIII administration, all three CAR Treg variants had similar division indices in vivo (WT 7.5 ± 0.8, ITAM1\textsuperscript{varepsilon} 7.3 ± 0.4, ITAM3\textsuperscript{varepsilon} 8.1 ± 2.2; Figure 2C). ITAM1\textsuperscript{varepsilon} CAR Tregs exhibited increased persistence in spleens of recipient BALB/c mice with a deletion in exon 16 of the F8 gene (F8e16\textsuperscript{varepsilon}–) as compared to WT CAR Tregs (0.30% ± 0.1% versus 0.12% ± 0.09%/splenic CD4+ T cells, day 3 post-adoptive transfer; Figure 2D). We incorporated the ITAM1\textsuperscript{varepsilon} mutation to all further modifications of the FVIII CAR construct.

The suppressive capacity of WT, ITAM1\textsuperscript{varepsilon}, and ITAM3\textsuperscript{varepsilon} FVIII CAR Tregs was then assessed in vivo. Naive BALB/c F8e16\textsuperscript{varepsilon}– recipient mice were infused with 5 × 10^5 sorted FVIII CAR Tregs, followed by 4 weekly intravenous (i.v.) injections of 1.5 international units (IU) BDD-FVIII (Figure 2E). To our surprise, adoptively transferred FVIII CAR Tregs were found to be immune stimulatory, escalating the formation of inhibitors in recipient animals (Figure 2F). Mice that received CAR Treg therapy developed high titer inhibitors (55.5 ± 6.4 BU/mL), as compared to controls that only received FVIII injections (7.3 ± 1.0 Bethesda unit [BU]/mL). In contrast, freshly isolated polyclonal thymic Tregs (tTregs; 1 × 10^6 tTregs) were suppressive (2.4 ± 1.7 BU/mL). zFVIII immunoglobulin G1 (IgG1) levels corroborated these findings (Figure 2G). Ex vivo expansion of CAR Tregs in the presence of rapamycin\textsuperscript{26} did not restore the suppressive function in FVIII CAR Tregs, although it was able to prevent inhibitor escalation to some extent (14.9 ± 5.4 BU/mL), indicating that signaling pathways downstream of CD3\varepsilon such as mTOR might regulate CAR signaling effects.
Dose-dependent dysregulation of signaling

We evaluated cytokine secretion and transcription factor co-expression by BDD-FVIII-stimulated CAR Tregs. Activated WT CAR Tregs produced high levels of IL-10, IL-4, and interferon (IFN)-γ, comparable to FVIII CAR Tconvs, and low levels of IL-2 and IL-17 at 48 h (Figure 3A). Intracellular staining confirmed a heterogenous cytokine profile in the transduced Treg population, with predominant expression of IFN-γ in the FoxP3+ population (Figures 3B and S3). This heterogenous profile
was also observed at the transcription factor level with upregulation of IRF4, T-bet, and GATA3, typically associated with either T helper (Th) 1 or Th2 response, as quantified by both flow cytometry and real-time RT-PCR (Figures 3C, 4A, and 4B).

We sought to understand the basis for this dysregulation by first looking at the effect of antigen dose. We speculate that tTregs might exhibit a high affinity for self-antigen at antigen doses that might be too low for Tconv stimulation.27 Whether high antigen dose can, in turn, destabilize Treg-suppressive function is not known.28 We performed an in vitro suppression assay to determine if FVIII CAR Tregs could suppress the proliferation of FVIII CAR Tconv responders when stimulated with high-dose (5 IU/mL) or low-dose (0.1 IU/mL) BDD-FVIII. Low-dose BDD-FVIII-stimulated FVIII CAR Tregs were able to suppress the proliferation of FVIII CAR Tconv even at low Treg:Tconv ratios (Figure 3D). This suppressive effect was lost on stimulation with high-dose BDD-FVIII. Non-specific suppression was observed at a high Treg:Tconv ratio, which could be attributed to competition for antigen and IL-2. We then performed phospho-flow analysis of signaling molecules downstream of TCR/CD3, which are amplified by CD28 engagement, such as the PI3K-PDK1-AKT and the MAPK/ERK pathways.29,30 We observed greatly enhanced phosphorylation of AKT (S473) and S6 kinases at 30/60 min, with a rapid transient response time for ERK at 10 min in high-dose, BDD-FVIII-stimulated FVIII CAR Tregs (Figure 3E). In contrast, dampened phosphorylation of AKT (T308), pAKT (S473), pS6, and pERK was seen in transduced Tregs on TCR triggering (anti-CD3/28 microbeads) or low-dose BDD-FVIII CAR stimulation. FVIII CAR Tconv triggered with CD3/28 microbeads were used as a positive control for pS6, pERK, and pAKT (S473), which confirmed that TCR signaling in Tconvs was much more robust as compared to Tregs (Figure S5A).
Figure 3. Altered cytokine, transcription factor expression, signaling, and in vitro suppression of FVIII CAR Tregs

(A) Detection of IL-2, IL-10, IL-4, IL-17, IL-35, and IFN-γ from supernatants of sorted and BDD-FVIII-stimulated FVIII CAR Tcons or Tregs at 48 h in vitro. Cells were cultured in the absence of exogenous IL-2. (B) Intracellular cytokine staining of cell-sorted FVIII CAR Tregs stimulated with high-dose (5 IU/mL) or low-dose (0.1 IU/mL) BDD-FVIII or left unstimulated (Ctrl) for 36 h in vitro. (C) Flow cytometric analysis for transcription factors: IRF4, T-bet, GATA3, and RORγt in cell-sorted and BDD-FVIII-stimulated FVIII CAR Tregs at 48 h in vitro. Unstimulated (Ctrl) or BDD-FVIII- or FIX-stimulated groups are indicated. (D) Normalized in vitro suppression of CTV-labeled FVIII CAR Tconv proliferation when co-cultured with FVIII CAR Tregs at the indicated Treg:Tconv ratios. Cells were stimulated with high-dose (5 IU/mL) or low-dose (0.1 IU/mL) BDD-FVIII or left unstimulated for 72 h in vitro. Percentage suppression calculated as (mean proliferation Tconv – mean proliferation Treg + Tconv) / mean proliferation Tconv) × 100%. (E)

(legend continued on next page)
the rate of pCD3ε, potentiates TCR signaling, and increase effector cytokine production, we generated targeted mutations in the CD28 signaling motifs, YMNM or PYAP, known to bind PI3K and LCK, respectively (Figure 4A). CD28-Y170F or CD28-AYAA substitution mutations did not negatively affect the upregulation of activation markers CD69, CD28, Ki67, or CTLA-4 in response to BDD-FVIII stimulation in vitro (Figure 4B). Notably, both the CD28-Y170F and CD28-AYAA mutations significantly reduced production of IFN-γ and IL-4 in BDD-FVIII-stimulated CAR Tregs, although this was also accompanied by diminished IL-10 production (Figure 4C). In vivo, however, CD28-Y170F and CD28-AYAA FVIII CAR Tregs were still unable to suppress inhibitor formation (4.25 ± 2.15, 9.1 ± 1.0, and 2.87 ± 1.58 BU/mL for control, CD28-Y170F, and CD28-AYAA groups, respectively, Figure 4D), although we did not observe the high inhibitor escalation seen in Figures 2F and 2G.

**Constitutive IL-10 expression does not restore CAR Treg function**

As a second strategy, we incorporated the murine IL-10 coding sequence downstream of the auto-cleaving P2A peptide sequence in WT, CD28-Y170F, or CD28-AYAA knock-in variants of FVIII CAR (Figure 5A). IL-10 is an important modulator in Tregs that is known to regulate the production of both Th1 and Th2 cytokines. IL-10 coding CARs constitutively produced IL-10 (1,617 ± 29.1 pg/C0), whereas both CD28-Y170F and CD28-AYAA CAR Tregs were unable to produce IL-10 (4.25 ± 2.15, 9.1 ± 1.0, and 2.87 ± 1.58 BU/mL for control, CD28-Y170F, and CD28-AYAA groups, respectively, Figure 4D), although we did not observe the high inhibitor escalation seen in Figures 2F and 2G.

**Constitutive IL-10 expression does not restore CAR Treg function**

As a second strategy, we incorporated the murine IL-10 coding sequence downstream of the auto-cleaving P2A peptide sequence in WT, CD28-Y170F, or CD28-AYAA knock-in variants of FVIII CAR (Figure 5A). IL-10 is an important modulator in Tregs that is known to regulate the production of both Th1 and Th2 cytokines.32,33 IL-10 coding CARs constitutively produced IL-10 (1,617 ± 29.1 pg/mL), which increased 1.3-fold on in vitro BDD-FVIII stimulation (Figure 5B). IFN-γ, IL-2, IL-17, IL-4, and tumor necrosis factor (TNF)-α levels were either completely abrogated or significantly diminished in IL-10-overexpressing WT, CD28-Y170F, or CD28-AYAA CAR Tregs (Figure 5B). Notably, IL-10 overexpression did not affect the ability of the CAR Tregs to proliferate in response to BDD-FVIII stimulation in vitro (Figure 5C). However, constitutive overexpression of IL-10 in adoptively transferred FVIII CAR Tregs or combined with targeted mutations in CD28 was unable to tolerate recipient BALB/c F8e16−/−mice (4.5 ± 1.5, 41.3 ± 9.2, 36 ± 12.3, and 29.1 ± 8.17 BU/mL for control, WT-IL-10, CD28-AYAA-IL-10, and CD28-Y170F-IL-10 cohorts, respectively; Figures 5D and 5E).

**Integration of TRuC into the TCR-CD3 complex regulates surface expression**

A recent report showed that fusing anti-CD19 scFv to the N termini of any of the five TCR subunits results in incorporation of TRuCs into the TCR-CD3 complex.34 This approach significantly improved tumor cell lysis as compared to high-affinity CD19-CAR T cells, which correlated with differences in intracellular signaling events between the two constructs. We fused FVIII scFv to murine CD3ε in order to generate FVIII TRuC Tregs (Figure 6A). FVIII TRuC was surface expressed in transduced Tregs and bound FVIIIFc in vitro (Figure 6B). However, we observed under conditions of reporter protein expression (mScarlet median fluorescence intensity [MFI]) that surface scFv expression, detected by the Fab antibody, was markedly lower for FVIII TRuC as compared to FVIII CAR (p = 0.0002; Figure 6C). This indicates that TRuC surface expression is limited by the number of TCR-CD3 complexes on the transduced Treg. In order to confirm FVIII TRuC integration into the TCR-CD3 complex, we co-transduced the murine T cell hybridoma 5KCε/β−, which are TCR-ε/β deficient, with FVIII TRuC or FVIII CAR and a murine TCR-ε/β-expressing construct. We observed that FVIII CAR was surface expressed, bound FVIIIFc, and upregulated the activation marker CD69 independent of TCR-ε/β expression (Figure 6D). In contrast, FVIIIFc binding and CD69 upregulation in FVIII TRuC-expressing 5KCε/β− cells were dependent on co-transduction with TCR-ε/β, which confirms that TRuC integrates into the TCR-CD3 complex (Figure 6D). Next, we tested the requirement for both TCR-ε/β and CD3 for TRuC incorporation. HEK293 cells were transfected with FVIII CAR or TRuC and either a murine TCR-ε/β- or CD38εεεεε-constructing or both. Whereas FVIIIFc binding by FVIII CAR was independent of TCR-ε/β or the CD3 complex, FVIII TRuC surface expression and FVIIIFc binding depended on co-transfection of both TCR-ε/β and CD3 (Figure 6F).34,35

**TRuC Tregs exhibit controlled signaling**

BDD-FVIII stimulation of FVIII TRuC Tregs in vitro led to upregulation of CD69, Ki67, CD28, and FoxP3 and a 5-fold increase in CTLA-4 expression (Figure 7A). In contrast to FVIII CAR Tregs, signaling molecules pAKT (S473), pERK, and pS6 were considerably dampened in TRuC Tregs, similar to levels observed on TCR triggering with anti-CD3/28 microbeads (Figure 7B). This was also confirmed by western blot for pERK and pS6 (Figure 7C). FVIII TRuC Tconvs triggered with CD3/28 microbeads were used as a positive control for pS6, pERK, and pAKT (S473), which confirmed that Tconv signaling was much more robust as compared to Tregs (Figure 5B).

Consistent with dampened signaling, BDD-FVIII-stimulated TRuC Tregs secreted significantly lower levels of cytokines IL-2, IL-4, IL-17, IL-10, and IFN-γ as compared to WT CAR Tregs (Figure 7D). This was also confirmed by intracellular cytokine staining (Figure 7A), which showed low but significantly elevated frequencies of IL-10 in BDD-FVIII-stimulated TRuC Tregs (Figure 7B) and insignificant IFN-γ expression. Similar to FVIII CAR Tregs, FVIII TRuC Tregs were able to suppress the in vitro proliferation of TRuC Tconvs responders when stimulated with low-dose (0.1 IU/mL) BDD-FVIII (Figure 7E). This suppressive effect was lost on stimulation with high-dose BDD-FVIII. We also tested to see if engineered Tregs induce cytolyis by evaluating granzyme B and CD107α upregulation. Neither CAR nor TRuC Treg upregulated cytolytic markers in response to BDD-FVIII or CD3/28 stimulation, whereas CAR and TRuC Tconvs exhibited a substantial increase in
both granzyme B and CD107a expression on CD3/28 stimulation and a less-significant increase on BDD-FVIII stimulation (Figures S8A and S8B).

TRuC Tregs are suppressive in vivo but have limited persistence

We investigated whether controlled signaling by TRuC Tregs was sufficient to maintain a suppressive phenotype in vitro and in vivo. In vivo, naïve BALB/c F8e16-/- recipient mice were infused with 5 × 10⁵ sorted TRuC Tregs or polyclonal tTregs (5 × 10⁵ or 1 × 10⁶) followed by 8 weekly i.v. injections of 1.5 IU BDD-FVIII (Figure 8A). FVIII TRuC Tregs were more effective at suppressing inhibitor formation as compared to polyclonal tTregs (Figures 8B and 8C). 7 out of 8 animals in the TRuC Treg group did not develop detectable inhibitors (average [avg] BU/mL 0.23 ± 0.23) at 4 weeks, whereas 100% of mice in the control group developed high-titer inhibitors >5 BU/mL (avg BU/mL 36.48 ± 9.66, p = 0.02). At 8 weeks, mice in the FVIII TRuC Treg group had a mean inhibitor titer of 15.4 ± 10.4 BU/mL as compared to the control group (avg BU/mL 151.4 ± 48.6, p = 0.004; Figure 8B). Anti-FVIII IgG1 titers were also significantly lower in the FVIII TRuC Treg group (5,238 ± 3,862 ng/mL) as compared to the polyclonal tTreg groups at 8 weeks (5 × 10⁵ tTreg group: 28,429 ± 3,862 ng/mL, p = 0.004, 1 × 10⁶ tTreg group: 2,1821 ± 8,020 ng/mL, p = 0.04), suggesting a more sustained tolerogenic effect for FVIII TRuC Tregs (Figure 8C). Although adoptively transferred Tregs persisted only transiently (7–14 days), we observed that BDD-FVIII stimulation was required for increased persistence in vivo. Repeated BDD-FVIII injections led to a 1.75-fold (p = 0.0001) and 1.17-fold (p = 0.036) higher numbers of CAR Tregs and TRuC Tregs, respectively, on day 3 (Figure 8D).

BDD-FVIII-stimulated CAR and TRuC Tregs maintain a Treg phenotype

We next asked whether BDD-FVIII stimulation would affect CAR and TRuC Treg stability. To address this, we performed repeated (daily) stimulations of CAR Treg and TRuC Treg with BDD-FVIII in vitro and evaluated their phenotype after each stimulation. FoxP3 frequencies were unchanged in both BDD-FVIII-stimulated CAR and TRuC Tregs (Figure 8E). PD1, LAP, CD69, and FoxP3 MFIs were significantly elevated in BDD-FVIII-stimulated CAR and TRuC Tregs, as compared to unstimulated controls or FIX-stimulated controls (Figure 8E).
Figure 5. IL-10-overexpressing FVIII CAR Tregs are not suppressive

(A) Schematic showing incorporation of the murine IL-10 sequence into WT, Y170F, or AYAA FVIII CAR constructs, separated by a P2A self-cleaving peptide sequence. (B) Effect of constitutive IL-10 expression on production of cytokines: IL-10, IL-4, IL-17, IFN-γ, IL-2, and TNF-α. Cell-sorted WT, WT-IL-10, CD28 AYAA-IL-10, or CD28 Y170F-IL-10 FVIII CAR Tregs were either left unstimulated (Ctrl) or stimulated with BDD-FVIII or FIX. Cell supernatants were estimated for cytokine production at 48 h in vitro. (C) CD28 AYAA-IL10 or CD28 Y170F-IL10 mutations do not adversely affect proliferation of activated FVIII CAR Tregs. In vitro proliferation of CTV-labeled WT-IL10, CD28 AYAA-IL10, and CD28 Y170F-IL10 FVIII CAR Tregs were left unstimulated (Ctrl) or stimulated with BDD-FVIII or FIX. Cell supernatants were estimated for cytokine production at 48 h in vitro. (D) Effect of constitutive IL-10 expression on production of cytokines: IL-10, IL-4, IL-17, IFN-γ, IL-2, and TNF-α. Cell-sorted WT, WT-IL-10, CD28 AYAA-IL-10, or CD28 Y170F-IL-10 FVIII CAR Tregs were either left unstimulated (Ctrl) or stimulated with BDD-FVIII or FIX. Cell supernatants were estimated for cytokine production at 48 h in vitro. (E) CD28 AYAA-IL10 or CD28 Y170F-IL10 mutations do not adversely affect proliferation of activated FVIII CAR Tregs. In vitro proliferation of CTV-labeled WT-IL10, CD28 AYAA-IL10, and CD28 Y170F-IL10 FVIII CAR Tregs were left unstimulated (Ctrl) or stimulated with BDD-FVIII or FIX. Cell supernatants were estimated for cytokine production at 48 h in vitro.

(legend continued on next page)
Finally, we analyzed the phenotype of sorted mScarlet FoxP3 GFP+ cells prior to and post-adoptive transfer into BALB/c F8e16−/− mice. Pre-adoptive transfer, mScarlet FoxP3 GFP+ cells were 92%–95% FoxP3+ with a good correlation between FoxP3 and GFP (Figure 8F). Cohorts of recipient mice were either left untreated or injected with BDD-FVIII every 2 days, starting 1 day post-adoptive transfer. On day 3 post adoptive transfer, splenic CD4+ T cells were magnetically enriched, and frequencies of mScarlet FoxP3 GFP+ cells were evaluated. mScarlet FoxP3 GFP+ CAR Treg and TRuC Treg both retained GFP expression, which correlated with FoxP3 expression (CAR Treg 93.18% ± 0.36%, TRuC Treg 92.75% ± 0.3% mScarlet FoxP3 GFP+ cells). Treg phenotype was not affected by BDD-FVIII stimulation in vivo (CAR Treg 93.71% ± 0.7%, TRuC Treg 90.54% ± 0.3% mScarlet FoxP3 GFP+ cells) (Figure 8F). Overall, these results demonstrate that CAR- and TRuC-mediated signaling preserves the regulatory phenotype of engineered Tregs.

DISCUSSION

Dysregulation of Treg signaling contributes to pathogenesis of many autoimmune conditions and highlights safety concerns in clinical Treg therapy. Cell-intrinsic molecular events responsible for this altered Treg function are not completely understood. Here, we redirected Treg specificity to clotting FVIII using two different approaches: expression of CAR or TRuC. We observed that CAR signaling can overstimulate signaling molecules and lead to a pro-inflammatory profile in transduced Tregs. We sought to understand the basis for this dysregulated profile by focusing on antigen or receptor dose/density and cytokine profile.

The magnitude of CAR signaling is dependent on scFv affinity, receptor density, antigen dose, choice of co-stimulatory molecule, and cytokine signals, among other factors. It is known that CAR scFv can bind to antigen with up to 1,000-fold higher affinity than TCRs, although the effect of affinity on signaling and functionality is not well studied. It can be agreed that CAR signaling in both Tconv and Treg is more rapid and intense compared to TCR stimulation. This result in over-activation and apoptosis of CAR Tconv affecting in vivo persistence. Over-activation and potentially fatal cytokine release syndrome are important safety concerns following administration of CAR T cell therapies for cancer. Approaches for tapering the magnitude of CAR signaling, such as introducing targeted mutations in CD3ζ ITAMs, have been carried out previously, with some success, although this strategy has not been tested for CAR Tregs. A decrease in the number of ITAM pairs from three to two or even one in the CAR construct can increase selectivity and prevent off-target effects by increasing the activation threshold. Our studies show that although Tregs are inherently more resistant to AICD, introducing the ITAM1 mutation in CD3ζ (CD247) improved CAR Treg persistence in vivo. Interestingly, tTregs are reported to preferentially express the alternatively spliced θ isoform of CD247, which naturally lacks the ITAM3 domain, rather than the CD3ζ isoform.

The TCR repertoire in Tregs is mostly distinct from that of Tconv, with an increased tendency toward self-specificity. Signals elicited by the TCR are greatly dampened in Tregs. This regulation is evident in both primary signal initiation and co-stimulatory signal potentiation, such that several signaling molecules like CD3ζ, SLP76, MAPK/ERK, AKT, or S6 and calcium flux are attenuated in Tregs. In particular, Tregs are shown to be defective in pAKT at S473, thus displaying reduced pAKT substrates. We confirmed a similar pattern of dampened signaling of these pathways upon TCR triggering of CAR-transduced Tregs, which was distinct from CAR Tconv signaling. Conversely, CAR stimulation of these same cells resulted in increased phosphorylation of many of these signaling mediators, including strong pAKT S473, affirming that CAR signaling differs from endogenous Treg signaling at multiple signaling nodes. We do not yet know the effect that unrestricted CD28ζ signaling would have on inhibitory signaling motifs such as the inhibitory immunoreceptor tyrosine-based inhibitory motif (ITIM) or the immunoreceptor tyrosine-based switch motif (ITSM) commonly over-expressed in Tregs such as CTLA-4, PD1, and T cell Ig and ITIM domain (TIGIT).

These motifs are responsible for the inhibition of TCR function and are thought to be critical for Treg-immunosuppressive function. For this study, we did not test the 4-1BB co-receptor as its incorporation into the CAR construct has previously been shown to be detrimental to Treg function.

It has been reported that Tregs can augment proliferation of T cells under strong stimulatory conditions. We were able to confirm this, as mice that were infused with FVIII CAR Tregs developed high inhibitor titers. Mutating either the PI3K or LCK binding motifs in the CD28 signaling domain partially controlled the exacerbation of inhibitors in recipient mice. However, this was insufficient to confer suppressive activity, as recipient mice still developed inhibitors in response to BDD-FVIII injections.

CAR Treg stimulation in vitro was accompanied by significant production of IFN-γ, TNF-α, IL-10, and IL-4. Altered cytokine production by CAR Tregs has also been reported in murine models of graft-versus-host disease (GVHD), where IFN-γ production by CAR Tregs as well as target cell lysis in a granzyme B-dependent manner was observed. Given that IL-10 has been shown to block antigen-specific T cell cytokines such as PI3K/AKT-induced IFN-γ by

10, or CD28 Y170F−IT-10 FVIII CAR Tregs, 72 h post-stimulation with low-dose (0.1 IU/mL) or high-dose (5 IU/mL) BDD-FVIII or no stimulation (Ctrl). Representative histogram plots to compare proliferation and graphical representation of division indices are shown. (D) 5 × 10^5 WT-IT-10, CD28 AYAA-IT-10, or CD28 Y170F−IT-10 FVIII CAR Tregs were adoptively transferred into BALB/c F8e16−/− recipient mice (n = 6–10/group). Mice received 4 weekly i.v. injections of 1.5 IU BDD-FVIII before functional inhibitors were assayed by the Bethesda assay. Control mice received only BDD-FVIII injections without cell transfer. (E) FVIII IgG1 ELISA for the same. Data points are averages ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.001 by 2-way ANOVA with Sidak’s comparisons for (B), 1-way ANOVA test with Tukey’s multiple comparisons for (C), and 1-way ANOVA test with Dunnett’s comparison for (D) and (E).
inhibiting the CD28 signaling pathway, we demonstrated that constitutive expression of murine IL-10 in FVIII CAR Tregs was able to completely abrogate IFN-γ production. However, IL-10-overexpressing FVIII CAR Tregs were unable to suppress the development of inhibitors in recipient mice, and combining IL-10 overexpression with CD28–YMMN or PYAP mutations did not contribute to suppression. Since IL-10 is also reported to promote the germinal center response and IgG class switching, additional studies are needed to determine the effect of IL-10 dose, constitutive versus inducible expression, and localized versus systemic IL-10 delivery for optimizing tolerability to FVIII.

An important consideration for CAR Tregs specific to soluble antigens like FVIII is whether contact-dependent mechanisms are essential for suppression, either via direct contact with antigen-bound B cell or dendritic cell or by modulation of antigen-presenting cell (APC) function via co-stimulatory molecule binding and/or trogocytosis. A recent report demonstrated transient suppressive activity of human CAR Tregs specific to the A2 domain of FVIII in a murine HA model, although the use of a xenogenic system made it difficult to fully determine the extent of suppression. It is not known whether the affinity of the A2 CAR used in that study was significantly lower to that of the BO2C11 antibody used here, which has a very high affinity of 10⁻¹⁴ M⁻¹. One notable difference between the two studies is that in vitro suppression was enhanced by the presence of autologous peripheral blood mononuclear cells (PBMCs), indicating a requirement for contact-mediated suppression, most likely with APC. We believe that these two independent studies are not contradictory but rather raise important questions about the role of scFv affinity and requirement for contact-dependent mechanisms of suppression.

We tested an alternative approach to engineer antigen-specific Tregs by tethering FVIII scFv to the CD3ε subunit of the TCR-CD3 complex, which can overcome the limitations of destabilizing effects mediated by rapid and strong CAR signaling. We and others observed TRuC to be expressed on the cell surface as a component of the TCR-CD3 complex. In fact, incorporation of TRuC into the TCR-CD3 complex regulated receptor density on the transduced cell surface, likely contributing to modulation of signaling. It is also possible that the TRuC-TCR-CD3 complex is subject to internalization and re-expression following single or repeated exposure to antigen, which further protects the transduced cell from chronic activation or exhaustion. Further studies are required to confirm this. A related study targeting a CAR to the TRAC locus was shown to avert tonic signaling in a mouse model of acute lymphoblastic leukemia by a mechanism of CAR internalization and post-stimulation replenishment of cell-surface CAR expression. TRuC’s ability to signal, whereas CARs utilize only the CD3ζ moiety of the complex with limited signaling capacity and lack intrinsic autoregulation, although recent studies indicate that CARs can interact with endogenous TCR molecules. FVIII TRuC Tregs were phenotypically stable and did not express cytolytic markers. Functionally,
FVIII TRuC Tregs were immunosuppressive and prevented the formation of inhibitors to FVIII.

In conclusion, we provide evidence that differences in signaling strength and kinetics via CAR and TRuC receptors can strongly affect Treg function. The incorporation of TCR-like signaling to engineered receptors has recently shown promise in multiple solid and liquid tumor models due to more controlled signaling and lower cytokine release. 20,65,66 Our data show that the TRuC platform can potentially improve the suppressive capacity of engineered Tregs in anti-drug antibody formation. The design of the next generation of antigen-specific Tregs will most likely emphasize finetuning activation in order to improve effectiveness and persistence, whereas reducing exhaustion and anergy. 45,66

**MATERIALS AND METHODS**

**Mice**

BALB/c Foxp3^{IRES-GFP} (Foxp3^{GFP}) mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). HA BALB/c F8e16^{−/−} mice were originally provided by Dr. David Scoult, Uniformed Services University, Bethesda, MD, USA. This B cell clone (BO2C11) produces IgG4 directed against amino acid residues 2,125–2,332 of human FVIII, which corresponds to the carboxyl-terminus of C1 (residues 2,125–2,172) and the C2 (residues 2,173–2,332) light-chain domains. 22 The scFv was constructed from the variable heavy (VH) and light (VL) sequences (Creative Biolabs, Shirley, NY, USA) and fused to second-generation murine 28z CAR signaling sequences (kind gift from Dr. Angelica Loskog, Uppsala University, Sweden). Hinge regions from either murine CD28 or in the CD28 signaling domains were introduced by site-directed mutagenesis (GenScript, Piscataway, NJ, USA). Murine IL-10 was cloned downstream of the CAR sequence, separated by a P2A cleavage sequence (GenScript, Piscataway, NJ, USA). FVIII-specific TRuC was generated by complexing the BO2C11 FVIII scFv sequence to the N terminus of murine CD3ε by a flexible linker (G4S)3X3 (GenScript, Piscataway, NJ, USA).

**Retroviral transduction**

FVIII CAR and TRuC sequences were inserted into the pMYs-IRES-mScarlet retroviral backbone. Transfer plasmids were transfected into the PlatE ecotropic retroviral packaging cell line (Cell Biolabs, San Diego, CA, USA) using either Viafect (Promega, Madison, WI, USA) or polyethylenimine (PEI) transfection reagents, and supernatants were collected after 48 h. CD4^{+}CD25^{−} Tconv or CD4^{+}CD25^{+} Tregs from BALB/c Foxp3^{GFP} mice were magnetically enriched using a mouse CD4^{+}CD25^{+} Treg isolation kit (Miltenyi Biotec, Auburn, CA, USA), further purified by cell sorting (FACSria II or FACSria SORP, BD Biosciences) and pre-activated for 48 h with a 1:1 bead-to-cell ratio using anti-CD3/28 mouse microbeads (Dynabeads; Invitrogen). High purity was ensured by a “four-way purity” sort followed by post-sort flow analysis (99.5% ± 0.3%). Tregs were cultured in Biologator serum-free medium (Biological Industries, Cromwell, CT, USA) supplemented with 5% fetal bovine serum (FBS; Atlanta Biologicals, Norcross, GA, USA), 10,000 IU/mL penicillin, 10 mg/mL streptomycin, 1 × Glutamax, 1 mM sodium pyruvate, 10 mM HEPES, 1 × nonessential amino acids, and 10 μM 2-mercaptoethanol. Clinical-grade recombinant hIL-2 (Proleukin/aldesleukin; Prometheus Therapeutics and Diagnostics, San Diego, CA, USA) was added at a final concentration of 1,000 IU/mL. Cells were transduced by spinoculation with retrovirus containing supernatants at 1,200 × g for 90 min in non-tissue culture-treated 6-well plates coated with 20 μg/mL retronectin (Takara Bio, Middleton, WI, USA). Transduced cells were further purified by sorting for Foxp3^{GFP+},mScarlet^{+} cells and ex vivo expanded for 3–4 days in the presence of anti-CD3/28 microbeads at a 1:1 bead-to-cell ratio. 100 nM rapamycin (LC laboratories, Woburn, MA, USA) was added under some conditions. Cells were rested for 4–6 h prior to functional in vitro or in vivo experiments (Figure 1B).

**Flow cytometry**

1 × 10^6 FVIII CAR- or TRuC-transduced Tconv or Tregs were plated in 12-well plates in Biotarget medium with 5% FBS without IL-2, before

*Figure 7. TRuC Tregs exhibit controlled signaling in vitro*

(A) Upregulation of Treg-associated activation markers CD69, K67, CD28, CTLA-4, and Foxp3 by BDD-FVIII-stimulated murine TRuC Tregs at 48 h in vitro. Controls include unstimulated cells or stimulation with an irrelevant protein, FIX. (B) Comparison of pERK (S473), pERK, or ps6 at indicated times following stimulation with low-dose (0.1 IU/mL) or high-dose (5 IU/mL) BDD-FVIII or TCR triggering with α-CD3/28 microbeads by flow cytometry for WT CAR (solid line) or TRuC (dotted line) Tregs. (C) Comparison of western blot analysis for pERK and ps6 at indicated times following stimulation with high-dose (5 IU/mL, blue line) or low-dose (0.1 IU/mL, pink line) BDD-FVIII. Densitometric analysis for pERK and ps6 for WT CAR Treg (solid line) or TRuC Treg (dotted line) is indicated. (D) Detection of IL-2, IL-10, IL-4, IL-17, and IFN-γ cytokines from BDD-FVIII-stimulated TRuC and CAR Treg cell supernatants at 48 h in vitro. (E) Normalized in vitro suppression of CTV-labeled FVIII TRuC Tconv proliferation when co-cultured with FVIII TRuC Tregs at the indicated Treg:Tconv ratios. Cells were stimulated with high-dose (5 IU/mL) or low-dose (0.1 IU/mL) BDD-FVIII or left unstimulated for 72 h in vitro. Percentage suppression calculated as ([mean proliferation Tconv – mean proliferation Treg + Tconv] / [mean proliferation Tconv]) × 100%. Data points are averages ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.001 by 1-way ANOVA with Dunnett’s comparisons for (A), multiple unpaired t tests for (B), 2-way ANOVA test with Tukey’s multiple comparison for (C) and (D), and 2-way ANOVA with Sidak’s multiple comparisons for (E).
stimulation with 0.1, 1, or 5 IU/mL of recombinant human BDD-FVIII (Xyntha; Pfizer, New York, NY, USA), FVIIIIfc (Bioverativ, Cambridge, MA, USA), FIXFc (Sanofi Genzyme, Cambridge, MA, USA), and anti-human Fc (5 mg/mL; BioLegend, San Diego, CA, USA) or anti-CD3/28 microbeads (1:1 bead-to-cell ratio). At 24–96 h, cells were first cultured with anti-CD16/32 and then stained using antibodies against CD4 (BV421), GITR (BV510), and RORcyt (BV421) from BD Biosciences (San José, CA, USA); CD69 (eFluor450), FoxP3 (eFluor660), GATA3 (PE/Cy7), and granzyme B (PerCP-eFluor 710) from eBioScience (San Diego, CA, USA); CD4 (BV421), CTLA-4 (BV421), PD1 (BV605), CD28 (PerCP/Cy5.5), LAP (PE), Ki67 (PE/Cy7), CD69 (PE/Cy7), CD49b (APC/Cy7), GFP (A488), IRF4 (PE), T-bet (BV605), anti-human IgG Fc (purified and AF647 conjugated), IL-10 (BV421), IL-4 (BV711), IL-17 (AF647), IFN-γ (AF700), and CD107a (BV711) from BioLegend (San Diego, CA, USA); and anti-goat Alexa Fluor 647 (Jackson ImmunoResearch, West Grove, PA, USA) were used for scFv surface detection. To analyze transcription factor expression, cells were first fixed with 2% paraformaldehyde and permeabilized using the Foxp3/Transcription Factor Staining Buffer (eBioScience, San Diego, CA, USA). Data were analyzed using FCS Express v7 (DeNovo Software, Los Angeles, CA, USA).

**Proliferation**

For an in vitro proliferation assay, cells were labeled with 3–5 μM CTV (Invitrogen, Carlsbad, CA, USA) prior to stimulation with BDD-FVIII or an irrelevant antigen (FIX; Benefix; Pfizer, New York, NY, USA) and incubated for 72 h at 37°C. CTV dilution in proliferating relative to unstimulated Tregs was quantified via proliferation analysis in FCS Express v7. For in vivo proliferation and persistence, WT, ITAM−/−, ITAM3− FVIII CAR Tregs, or TRuC Tregs were purified by FACS and labeled with 3–5 μM CTV. 1 × 10^6 Tregs were adoptively transferred into recipient BALB/c F8b16−/− mice (n = 4/group), and 1 day later, mice were i.v. injected with 1.5 IU BDD-FVIII or left untreated. Mice were euthanized on days 3, 7, and 14 following adoptive transfer. Spleen CD4+ T cells were magnetically enriched, and CTV+ FoxP3<sup>+</sup>GFP+ mScarlet<sup>+</sup> cells were quantified on a BD LSR Fortessa.

**In vitro suppression**

For in vitro suppression, WT FVIII CAR or FVIII TRuC Tregs were purified by sorting and incubated with 3–5 μM CTV-labeled FVIII CAR Tconv or FVIII TRuC Tconv responder cells, respectively, at varying ratios of Treg:Tconv, whereas keeping Tconv numbers constant. Cells were stimulated with either high-dose (5 IU/mL) or low-dose (0.1 IU/mL) BDD-FVIII and acquired on a BD LSR Fortessa after 72 h at 37°C. Dilution of CTV in proliferating CAR Tconv or TRuC Tconv was quantified relative to unstimulated cells using proliferation analysis in FCS Express v7.

**Cytokine detection**

For intracellular cytokine staining, FVIII CAR- or TRuC-transduced cells were plated in 12-well plates in Biotarget medium with 5% FBS without IL-2 before stimulation with 5 IU/mL of BDD-FVIII, FIX, or anti-CD3/28 microbeads (1:1 bead-to-cell ratio). Following 20–32 h of stimulation, Brefeldin A (3 μg/mL; eBioScience, San Diego, CA, USA) was added for an additional 4 h. Cells were fixed and permeabilized with CytoFast Fix/Perm Buffer (BioLegend), and intracellular cytokine staining was performed for flow cytometry analysis. Additionally, supernatants were collected from stimulated cells at 48 h, and levels of IL-2, IL-4, IL-10, IL-35, IL-17, IL-21, and IFN-γ were quantified by the DuoSet ELISA kits according to the manufacturer’s recommendations (R&D Systems, Minneapolis, MN, USA).

**Phospho flow**

1 × 10^5 FVIII CAR or TRuC Tconv or Tregs/well were plated in a 12-well plate in Biotarget medium without FBS or IL-2. Cells were stimulated with BDD-FVIII or anti-CD3/28 microbeads for 0, 10, 30, and 60 min, following which, cells were immediately fixed with 2% paraformaldehyde. Fixed cells were permeabilized with 90% methanol for 30 min, followed by staining for pERK (APC), pS6 (PacBlue), pAKT (S473, PE, APC), and pAkt (T308, APC; Cell Signaling Technology, Danvers, MA, USA), and analyzed by flow cytometry on a BD LSR Fortessa.

**Western blot**

CAR or TRuC Tregs were stimulated and fixed as described in phospho flow. Fixed cells were lysed in ice-cold radioimmunoprecipitation assay (RIPA) buffer containing protease and phosphatase inhibitors (Cell Signaling Technology, Danvers, MA, USA). PAGE-separated lysates were transferred to polyvinylidene fluoride (PVDF) membranes (Transblot Turbo; Bio-Rad, Hercules, CA, USA). Membranes were probed for p65, pERK, and β-actin (Cell Signaling Technology, Danvers, MA, USA), signal detected on

---

**Figure 8. TRuC Tregs maintain a suppressive phenotype in vivo**

(A) Timeline for assessing in vivo prevention of inhibitor formation by TRuC Treg cellular therapy. 5 × 10^6 TRuC Treg and 5 × 10^6 or 1 × 10^6 freshly isolated Tregs were adoptively transferred into BALB/c F8b16−/− recipient mice (n = 5–8/group). Mice received 4 weekly i.v. injections of 1.5 IU BDD-FVIII, and plasma samples were analyzed after the 4th and 8th injection for (B) functional inhibitors by Bethesda assay and (C) α-FVIII IgG1 ELISA. Control mice received only BDD-FVIII injections without Treg transfer. (D) In vivo persistence of 1 × 10^6 adoptively transferred FVIII CAR or TRuC Tregs following 3 ×/week BDD-FVIII (+FVIII) or mock (−FVIII) injections (n = 3/group). Total number of adoptively transferred (mScarlet<sup>+</sup>, FoxP3<sup>+</sup>, GFP<sup>+</sup>) engineered Tregs per 1 × 10^6 splenic CD4<sup>+</sup> T cells is indicated on days 3, 7, and 14 post-adoptive transfer. (E) Effect of repeated in vitro BDD-FVIII stimulations on the phenotype of FVIII CAR or TRuC Tregs. Expression of PD1, CD69, LAP, CTLA-4, and FoxP3 and frequencies of FoxP3<sup>+</sup> cells were estimated at each time point following 4 daily stimulations with BDD-FVIII. Controls were either mock stimulated or stimulated with an irrelevant antigen, FIX. Solid lines represent CAR Tregs, and dotted lines represent TRuC Tregs. (F) In vivo Treg stability of 1 × 10^6 FVIII CAR or TRuC Tregs assessed pre- and post-adoptive transfer in BALB/c F8b16−/− recipient mice (n = 6/group). One-half of the recipient animals received 2 daily BDD-FVIII injections. Representative density plots and bar graph of mScarlet and FoxP3<sup>+</sup> co-expression following BDD-FVIII (+FVIII) or mock (−FVIII) injection are indicated on day 3. (F) Data points are averages ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.001 by 2-way ANOVA with Sidak’s multiple comparisons for (B) and (C) and 2-way ANOVA with Tukey’s multiple comparisons for (D)–(F).
Inhibitor establishment and analysis of plasma samples
BALB/c F8e16-/- HA mice (n = 5–10) received weekly i.v. administrations of 1.5 IU BDD-FVIII. Mice received 5 × 10^5 FVIII CAR or TruCT Tregs 1 day prior to starting BDD-FVIII injections (Figures 2E and 7B). At 1- and 2-month time points post-adoptive transfer, ~200 µL blood was collected from the retroorbital plexus using non-treated capillary tubes into 3.8% sodium citrate, and plasma was analyzed for inhibitor formation by the Bethesda assay (measured as the reciprocal of the dilution of test plasma at which 50% of FVIII activity is inhibited).

Statistical analysis
Data shown are mean ± SEM. Statistical significance was determined using the Student’s t-test, 1-way or 2-way ANOVA, and multiple comparisons were made using Dunnett’s, Tukey’s, Sidak’s, or Kruskal-Wallis post-tests as indicated, using GraphPad Prism 8 software (GraphPad, La Jolla, CA, USA). Values at p < 0.05 were deemed significant and indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Frequencies of mice that developed inhibitors were compared using Fisher’s exact test.

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.ymthe.2021.04.034.

ACKNOWLEDGMENTS
We would like to thank Dr. Amanda Posgai for critical editing of the manuscript. We would like to acknowledge the Flow Cytometry Core Facility at Indiana University Simon Cancer Center for cell-sorting services and the Center for Immunology and Transplantation at the University of Florida. Murine CD3 WTdelta-F2A-gamma-T2A-epsilon-P2A-zeta pMIA II (Addgene plasmid #52093) and murine TCR OTI-2A.pMIG II (Addgene plasmid #52111) were a gift from Dr. Dario Vignali. We would like to thank Dr. Maki Nakayama for the kind gift of the 5KCαβ- regulatory T cells generated using the 5KCαβ- marrow T cell line (NIDDK grant P30DK116073). M.B. is in receipt of a career development award from the National Hemophilia Foundation (NHF). T.M.B. is supported by grants from the National Institutes of Health (P01 AI42288 and R01 DK116073). M.B. is in receipt of a career development award from the National Hemophilia Foundation (P01 AI42288 and R01 DK116073) and The Leona M. and Harry B. Helmsley Charitable Trust.

AUTHOR CONTRIBUTIONS
J.R., S.R.P.K., D.J.P., R.S., M.M.-M., and M.B. performed experiments. J.R., S.R.P.K., D.J.P., T.M.B., and M.B. designed experiments and analyzed and interpreted data. T.M.B. and M.B. wrote the manuscript and supervised the study.

DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES
1. Bluestone, J.A., Buckner, J.H., Fitch, M., Gitelman, S.E., Gupta, S., Hellerstein, M.K., Harold, K.C., Lores, A., Lee, M.R., Li, K., et al. (2015). Type I diabetes immunotherapy using polyclonal regulatory T cells. Sci. Transl. Med. 7, 315ra189.
2. D’Alia, M., Pauli, M.L., Remedios, K., Taravati, K., Sandova, P.M., Putnam, A.L., Lores, A., Haemel, A., Tang, Q., Hellerstein, M., et al. Autoimmunity Centers of Excellence (2019). Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus. Arthritis Rheumatol. 71, 431–440.
3. Sawitzki, B., Harden, P.N., Reinke, P., Moreau, A., Hutchinson, J.A., Game, D.S., Tang, Q., Guinan, E.C., Battaglia, M., Burlingham, W.J., et al. (2020). Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet 395, 1627–1639.
4. Di Ianni, M., Falletti, F., Carotti, A., Terenzi, A., Castellino, F., Bonafacio, E., Del Papa, B., Zei, T., Ostini, R.I., Cocchini, D., et al. (2011). Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117, 3921–3928.
5. Noyan, F., Zimmermann, K., Hardtke-Wolenski, M., Knoefel, A., Schulde, E., Geffers, R., Hult, M., Huehn, J., Galli, M., Morgan, M., et al. (2017). Prevention of Allograft Rejection by Use of Regulatory T Cells With an MHC-Specific Chimeric Antigen Receptor. Am. J. Transplant. 17, 917–930.
6. Bluestone, J.A., and Tang, Q. (2018). Tregs cells—the next frontier of cell therapy. Science 362, 154–155.
7. Srivastava, S., and Riddell, S.R. (2018). Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy. J. Immunol. 200, 459–468.
8. Honaker, Y., Hubbard, N., Xiang, Y., Fisher, L., Hagin, D., Sommer, K., Song, Y., Yang, S.J., Lopez, C., Tappen, T., et al. (2020). Gene editing to induce FOXP3 expression of CD4+ T cells leads to a stable regulatory phenotype and function. Sci. Transl. Med. 12, eaay6422.
9. Allan, S.E., Alist, A.N., Merindol, N., Crellin, N.K., Amendola, M., Bachetta, R., Naldini, L., Roncarolo, M.G., Soudney, H., and Leving, M.K. (2008). Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol. Ther. 16, 194–202.
10. Fu, R.Y., Chen, A.C., Lyle, M.J., Chen, C.Y., Liu, C.L., and Miao, C.H. (2020). CD4+ T cells engineered with FVIII-CAR and murine Foxp3 suppress anti-factor VIII immune responses in hemophilia a mice. Cell. Immunol. 358, 104216.
11. Blat, D., Zigmmond, E., Altheber, Z., Waks, T., and Eshhar, Z. (2014). Alloantigen-specific CD4+ T regulatory cells target the CNS and suppress EAE upon intranasal delivery. Sci. Transl. Med. 6, 242ra87.
12. Fransson, M., Papa, B., Zei, T., Ostini, R.J., Bencsics, D., et al. (2011). Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117, 3921–3928.
Hertzog, R.W., Kuteyeva, V., Saboungi, R., Terhorst, C., and Biwias, M. (2019). Reprogrammed CD4+ T Cells That Express FexP3 Control Inhibitory Antibody Formation in Hemophilia A Mice. Front. Immunol. 10, 274.

Baeuerle, P.A., Ding, J., Patel, E., Thorausch, N., Horton, H., Gierut, J., Scarfo, I., Choudhary, R., Kiner, O., Krishnamurthy, J., et al. (2019). Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. Nat. Commun. 10, 2087.

Acuto, O., Di Bartolo, V., and Michel, F. (2008). Tailoring T-cell receptor signals by proximal negative feedback mechanisms. Nat. Rev. Immunol. 8, 699–712.

Jacquemin, M.G., Desqueper, B.G., Benhida, A., Vander Elst, L., Hoylaerts, M.F., Bakkus, M., Thielemanns, K., Arnout, J., Peerlinck, K., Gilles, J.G., et al. (1998). Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 92, 496–506.

Thill, P.A., Weiss, A., and Chakrabartey, A.K. (2016). Phosphorylation of a Tyrosine Residue on Zap70 by Lck and Its Subsequent Binding via an SH2 Domain May Be a Key Gatekeeper of T Cell Receptor Signaling In Vivo. Mol. Cell. Biol. 36, 2396–2402.

Love, P.E., and Hayes, S.M. (2010). ITAM-mediated signaling by the T-cell antigen receptor. Cold Spring Harb. Perspect. Biol. 2, a004285.

Ardouin, L., Boyer, C., Gillet, A., Larner, A.C., and Finbloom, D.S. (1999). Interleukin-10 inhibits expression of both IL-2 and TNF-α in Th1 cells. J. Immunol. 162, 1969–1978.

Turner, M.S., Kane, L.P., and Morel, P.A. (2009). Dominant role of antigen dose in breaking their anergic/suppressive state. Int. Immunol. 105, 4743–4748.

Takahashi, T., Kuniyasu, Y., Toda, M., Sakaguchi, N., Itoh, M., Iwata, M., Shimizu, J., Takahashi, T., Kuniyasu, Y., Toda, M., Sakaguchi, N., Itoh, M., Iwata, M., Shimizu, J., and Sakaguchi, S. (1998). Immunologic self-tolerance maintained by CD25+CD4+ Foxp3+ Regulatory T Cells. J. Exp. Med. 188, 2225–2234.

Deriu, F., Novelli, M., Menceri, S., Degli Esposti, S., and Ferri, A. (2019). CD28 and the tyrosine kinase lck stimulate mitogen-activated protein kinase activity in T cells via inhibition of the small G protein Rap1. Mol. Cell. Biol. 20, 9492–9502.

Kane, L.P., and Weiss, A. (2003). The PI-3 kinase/Akt pathway and T cell activation: pleiotropic pathways downstream of PIP3. Immunol. Rev. 192, 70–79.

Carey, K.D., Dillon, T.J., Schmitt, J.M., Baird, A.M., Holdorf, A.D., Straus, D.B., Shaw, A.S., and Stork, P.J. (2000). CD28 and the tyrosine kinase lck stimulate mitogen-activated protein kinase activity in T cells. J. Immunol. 165, 9492–9502.

Fitzgerald, J.C., Weiss, S.L., Lacey, S.F., Melenhorst, J.S., Shaw, P., Berg, R.A., June, C.H., Porter, D.L., et al. (2017). Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Crit. Care Med. 45, e124–e131.

Zhao, Y., Wang, Q.J., Yang, S., Kochenderfer, J.N., Zheng, Z., Zhong, X., Sadelain, M., Eshhar, Z., Rosenberg, S.A., and Morgan, R.A. (2009). A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 183, 5563–5574.

Kochenderfer, J.N., Yu, Z., Frasheri, D., Restifo, N.P., and Rosenberg, S.A. (2010). Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116, 3875–3886.

Feucht, J., Sun, J., Eyyem, J., Ho, Y.J., Zhao, Z., Leibold, J., Dobrin, A., Cabriolu, A., Hamieh, M., and Sadelain, M. (2019). Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat. Med. 25, 82–88.

James, J.R. (2018). Tuning ITAM multiplicity on T cell receptors can control potency and selectivity to ligand density. Sci. Signal. 11, eaan1088.

Hawse, W.F., Boggs, W.C., and Morel, P.A. (2017). TCR Signal Strength Regulates Akt Substrate Specificity To Induce Alternate Murine Th and T Regulatory Cell Differentiation Programs. J. Immunol. 199, 589–597.

Stritesky, G.L., Jameson, S.C., and Hogquist, K.A. (2012). Selection of self-reactive T cells in the thymus. Annu. Rev. Immunol. 30, 95–114.

Yan, D., Farache, J., Mingueneau, M., Mathis, D., and Benoit, C. (2015). Simulated signal transduction in regulatory T cells expressing the transcription factor FoxP3. Proc. Natl. Acad. Sci. USA 112, 14942–14947.

Cresswind, N.K., Garcia, R.V., and Leving, M.K. (2007). Alteration of AKT prevents suppressed function of human CD4+CD25+ T regulatory cells. Blood 109, 2014–2022.

Molineri, L.L., Miller, M.L., Evaristo, C., and Alegrey, M.L. (2011). High TCR stimuli prevent induced regulatory T cell differentiation in a NF-κB-dependent manner. J. Immunol. 186, 4696–4671.

Kurtulus, S., Sakushi, K., Ngiow, S.F., Joller, N., Tan, D.J., Teng, M.W., Smyth, M.J., Kuchroo, V.K., and Anderson, A.C. (2015). TIGIT predominantly regulates the immune response via regulatory T cells. J. Clin. Invest. 125, 4053–4062.

Giancachhi, E., and Farabbacci, A. (2018). Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression. Front. Immunol. 9, 2374.

Bozorgi, A.C., Larson, R.C., Choi, B.D., Bouffard, A.A., Riley, L.S., Schifferle, E., Kulkarni, A.S., Getrucl, C.L., Ting, D., Blazar, B.R., et al. (2019). Chimeric antigen receptor costimulation domains modulate human regulatory T cell function. JCI Insight 5, e126194.

Boardman, D.A., Philippou, C., Fruhwirth, G.O., Ibrahim, M.A., Hanno, R.F., Cooper, D., Marelli-Berg, E.M., Watt, F.M., Lechler, R.I., Maher, J., et al. (2017). Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection. Am. J. Transplant. 17, 931–943.

Cao, X., Cai, S.F., Fehninger, T.A., Song, J., Collins, L.L., Piwnica-Worms, D.R., and Ley, T.J. (2007). Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27, 635–646.
57. Joss, A., Akdis, M., Faith, A., Blaser, K., and Akdis, C.A. (2000). IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. Eur. J. Immunol. 30, 1683–1690.

58. Kitz, A., de Marcken, M., Gautron, A.S., Mitrovic, M., Hafler, D.A., and Dominguez-Villar, M. (2016). AKT isoforms modulate Th1-like Treg generation and function in human autoimmune disease. EMBO Rep. 17, 1169–1183.

59. Laidlaw, B.J., Lu, Y., Amezquita, R.A., Weinstein, J.S., Vander Heiden, J.A., Gupta, N.T., Kleinstein, S.H., Kaech, S.M., and Craft, J. (2017). Interleukin-10 from CD4+ follicular regulatory T cells promotes the germinal center response. Sci. Immunol. 2, eaan4767.

60. Saxena, A., Khosraviani, S., Noel, S., Mohan, D., Donner, T., and Hamad, A.R. (2015). Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine 74, 27–34.

61. Guthmiller, J.J., Graham, A.C., Zander, R.A., Pope, R.L., and Butler, N.S. (2017). Cutting Edge: IL-10 Is Essential for the Generation of Germinal Center B Cell Responses and Anti-Plasmodium Humoral Immunity. J. Immunol. 198, 617–622.

62. Akkaya, B., Oya, Y., Akkaya, M., Al Souz, J., Holstein, A.H., Kamenyeva, O., Kabat, J., Matsumura, R., Dorward, D.W., Glass, D.D., and Shevach, E.M. (2019). Regulatory T cells mediate specific suppression by depleting peptide-MHC class II from dendritic cells. Nat. Immunol. 20, 218–231.

63. Yoon, J., Schmidt, A., Zhang, A.H., Königs, C., Kim, Y.C., and Scott, D.W. (2017). FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII. Blood 129, 238–245.

64. Delignat, S., Russick, J., Gangadharan, B., Rayes, J., Ing, M., Voorberg, J., Kaveri, S.V., and Lacroix-Desmazes, S. (2019). Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A. Haematologica 104, 1046–1054.

65. Liu, H., Rhodes, M., Wiest, D.L., and Vignali, D.A. (2000). On the dynamics of TCR-CD3 complex cell surface expression and downmodulation. Immunity 13, 665–675.

66. Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S.J., Hamieh, M., Cunanan, K.M., Odak, A., Gönen, M., and Sadelain, M. (2017). Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543, 113–117.

67. Schamel, W.W., Alarcon, B., Höfer, T., and Minguet, S. (2017). The Allostery Model of TCR Regulation. J. Immunol. 198, 47–52.

68. Ramello, M.C., Benzaid, I., Kuenzi, B.M., Lienlaf-Moreno, M., Kandell, W.M., Santiago, D.N., Pabón-Saldaña, M., Darville, L., Fang, B., Rin, U., et al. (2019). An immunoproteomic approach to characterize the CAR interactome and signalosome. Sci. Signal. 12, eaap9777.

69. Liu, Y., Liu, G., Wang, J., Zheng, Z.Y., Jia, L., Rui, W., Huang, D., Zhou, Z.X., Zhou, L., Wu, X., et al. (2021). Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci. Transl. Med. 13, eabb5191.

70. Xu, Y., Yang, Z., Horan, L.H., Zhang, P., Liu, L., Zimdahl, B., Green, S., Lu, J., Morales, J.F., Barrett, D.M., et al. (2018). A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release. Cell Discov. 4, 62.

71. Betts, M.R., Brenchley, J.M., Price, D.A., De Rosa, S.C., Douek, D.C., Roederer, M., and Koup, R.A. (2003). Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281, 65–78.

72. Cao, O., Hofman, B.E., Moghimi, B., Nayak, S., Cooper, M., Zhou, S., Erll, H.C., High, K.A., and Herzog, R.W. (2009). Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol. Ther. 17, 1733–1742.

73. Biswas, M., Rogers, G.L., Sherman, A., Byrne, B.I., Markusic, D.M., Jiang, H., and Herzog, R.W. (2017). Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin. Thromb. Haemost. 117, 33–43.